Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMvent: risankizumab versus adalimumab in moderate to severe plaque psoriasis
2015-003623-65Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Risankizumab with Adalimumab (2 arms). Primary endpoint: PASI 90 at Week 16. Started Jan 2016; status: completed.
02
Drugs
risankizumabadalimumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-003623-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003623-65.